WO2016184793A1 - Méthodes de traitement de patients souffrant d'un adénocarcinome rénal métastatique résistant aux inhibiteurs du vegfr - Google Patents
Méthodes de traitement de patients souffrant d'un adénocarcinome rénal métastatique résistant aux inhibiteurs du vegfr Download PDFInfo
- Publication number
- WO2016184793A1 WO2016184793A1 PCT/EP2016/060806 EP2016060806W WO2016184793A1 WO 2016184793 A1 WO2016184793 A1 WO 2016184793A1 EP 2016060806 W EP2016060806 W EP 2016060806W WO 2016184793 A1 WO2016184793 A1 WO 2016184793A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sunitinib
- cells
- patient
- combination
- weak base
- Prior art date
Links
- 206010050513 Metastatic renal cell carcinoma Diseases 0.000 title claims abstract description 52
- 238000000034 method Methods 0.000 title claims abstract description 47
- 229940124674 VEGF-R inhibitor Drugs 0.000 title abstract description 4
- 239000003814 drug Substances 0.000 claims abstract description 70
- 229940079593 drug Drugs 0.000 claims abstract description 69
- 238000011282 treatment Methods 0.000 claims abstract description 52
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims abstract description 46
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims abstract description 46
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims abstract description 45
- 239000003112 inhibitor Substances 0.000 claims abstract description 36
- 229940079156 Proteasome inhibitor Drugs 0.000 claims abstract description 27
- 239000003207 proteasome inhibitor Substances 0.000 claims abstract description 27
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 21
- 230000002080 lysosomotropic effect Effects 0.000 claims abstract description 15
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims description 156
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims description 155
- 229960001796 sunitinib Drugs 0.000 claims description 155
- 108091008605 VEGF receptors Proteins 0.000 claims description 58
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims description 56
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 claims description 55
- 108090000623 proteins and genes Proteins 0.000 claims description 42
- 230000014509 gene expression Effects 0.000 claims description 36
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 34
- 208000019465 refractory cytopenia of childhood Diseases 0.000 claims description 31
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 claims description 25
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 claims description 22
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 claims description 22
- 229950005476 elacridar Drugs 0.000 claims description 22
- OSFCMRGOZNQUSW-UHFFFAOYSA-N n-[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]-5-methoxy-9-oxo-10h-acridine-4-carboxamide Chemical compound N1C2=C(OC)C=CC=C2C(=O)C2=C1C(C(=O)NC1=CC=C(C=C1)CCN1CCC=3C=C(C(=CC=3C1)OC)OC)=CC=C2 OSFCMRGOZNQUSW-UHFFFAOYSA-N 0.000 claims description 22
- 230000004083 survival effect Effects 0.000 claims description 20
- 206010027476 Metastases Diseases 0.000 claims description 14
- 102100029081 Proteasome subunit beta type-10 Human genes 0.000 claims description 14
- 101001124792 Homo sapiens Proteasome subunit beta type-10 Proteins 0.000 claims description 13
- 101001080429 Homo sapiens Proteasome inhibitor PI31 subunit Proteins 0.000 claims description 12
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 12
- 230000009401 metastasis Effects 0.000 claims description 12
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 claims description 11
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 11
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims description 11
- 238000001574 biopsy Methods 0.000 claims description 11
- 229960001467 bortezomib Drugs 0.000 claims description 11
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 claims description 8
- 229960003677 chloroquine Drugs 0.000 claims description 8
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 claims description 8
- 229930192649 bafilomycin Natural products 0.000 claims description 6
- XDHNQDDQEHDUTM-UHFFFAOYSA-N bafliomycin A1 Natural products COC1C=CC=C(C)CC(C)C(O)C(C)C=C(C)C=C(OC)C(=O)OC1C(C)C(O)C(C)C1(O)OC(C(C)C)C(C)C(O)C1 XDHNQDDQEHDUTM-UHFFFAOYSA-N 0.000 claims description 6
- 238000010837 poor prognosis Methods 0.000 claims description 6
- KCOYQXZDFIIGCY-CZIZESTLSA-N (3e)-4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1,3-dihydrobenzimidazol-2-ylidene]quinolin-2-one Chemical compound C1CN(C)CCN1C1=CC=C(N\C(N2)=C/3C(=C4C(F)=CC=CC4=NC\3=O)N)C2=C1 KCOYQXZDFIIGCY-CZIZESTLSA-N 0.000 claims description 3
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims description 3
- 229960003005 axitinib Drugs 0.000 claims description 3
- SJFBTAPEPRWNKH-CCKFTAQKSA-N delanzomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)C1=CC=CC(C=2C=CC=CC=2)=N1 SJFBTAPEPRWNKH-CCKFTAQKSA-N 0.000 claims description 3
- 229950005778 dovitinib Drugs 0.000 claims description 3
- XEEQGYMUWCZPDN-DOMZBBRYSA-N (-)-(11S,2'R)-erythro-mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 claims description 2
- 229930191564 Monensin Natural products 0.000 claims description 2
- GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 claims description 2
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 claims description 2
- LGGHDPFKSSRQNS-UHFFFAOYSA-N Tariquidar Chemical compound C1=CC=CC2=CC(C(=O)NC3=CC(OC)=C(OC)C=C3C(=O)NC3=CC=C(C=C3)CCN3CCC=4C=C(C(=CC=4C3)OC)OC)=CN=C21 LGGHDPFKSSRQNS-UHFFFAOYSA-N 0.000 claims description 2
- CGVWPQOFHSAKRR-NDEPHWFRSA-N biricodar Chemical compound COC1=C(OC)C(OC)=CC(C(=O)C(=O)N2[C@@H](CCCC2)C(=O)OC(CCCC=2C=NC=CC=2)CCCC=2C=NC=CC=2)=C1 CGVWPQOFHSAKRR-NDEPHWFRSA-N 0.000 claims description 2
- 229950005124 biricodar Drugs 0.000 claims description 2
- 229960002438 carfilzomib Drugs 0.000 claims description 2
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 claims description 2
- 108010021331 carfilzomib Proteins 0.000 claims description 2
- 229950001466 delanzomib Drugs 0.000 claims description 2
- 229960001962 mefloquine Drugs 0.000 claims description 2
- 229960005358 monensin Drugs 0.000 claims description 2
- GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 claims description 2
- 229960005019 pantoprazole Drugs 0.000 claims description 2
- 229950005890 tariquidar Drugs 0.000 claims description 2
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 claims 2
- 101001136986 Homo sapiens Proteasome subunit beta type-8 Proteins 0.000 claims 1
- 102100035760 Proteasome subunit beta type-8 Human genes 0.000 claims 1
- 229940123429 VEGFR tyrosine kinase inhibitor Drugs 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 154
- 206010028980 Neoplasm Diseases 0.000 description 50
- 210000003712 lysosome Anatomy 0.000 description 45
- 230000001868 lysosomic effect Effects 0.000 description 45
- 201000011510 cancer Diseases 0.000 description 31
- 230000004900 autophagic degradation Effects 0.000 description 29
- 230000000694 effects Effects 0.000 description 28
- 230000035508 accumulation Effects 0.000 description 25
- 238000009825 accumulation Methods 0.000 description 25
- 230000002132 lysosomal effect Effects 0.000 description 25
- 101710094466 Proteasome subunit beta type-9 Proteins 0.000 description 23
- 102000017473 Proteasome subunit beta type 8 Human genes 0.000 description 22
- 108050005569 Proteasome subunit beta type 8 Proteins 0.000 description 22
- 150000007523 nucleic acids Chemical group 0.000 description 19
- 230000030833 cell death Effects 0.000 description 18
- 230000001965 increasing effect Effects 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 18
- 239000012472 biological sample Substances 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 15
- 230000009919 sequestration Effects 0.000 description 15
- 210000004881 tumor cell Anatomy 0.000 description 15
- 230000005764 inhibitory process Effects 0.000 description 14
- 102000039446 nucleic acids Human genes 0.000 description 14
- 108020004707 nucleic acids Proteins 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 13
- 230000007246 mechanism Effects 0.000 description 12
- 101000837845 Homo sapiens Transcription factor E3 Proteins 0.000 description 11
- 102100028507 Transcription factor E3 Human genes 0.000 description 11
- 230000003833 cell viability Effects 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 238000011534 incubation Methods 0.000 description 10
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 10
- 230000003321 amplification Effects 0.000 description 9
- 238000003199 nucleic acid amplification method Methods 0.000 description 9
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 description 8
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 8
- 102100022594 ATP-binding cassette sub-family G member 1 Human genes 0.000 description 8
- 108010090314 Member 1 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 238000003364 immunohistochemistry Methods 0.000 description 8
- 239000012981 Hank's balanced salt solution Substances 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000003527 anti-angiogenesis Effects 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 239000013615 primer Substances 0.000 description 7
- 239000002987 primer (paints) Substances 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 108010078791 Carrier Proteins Proteins 0.000 description 6
- 102100023580 Cyclic AMP-dependent transcription factor ATF-4 Human genes 0.000 description 6
- 101000898449 Homo sapiens Cathepsin B Proteins 0.000 description 6
- 230000006978 adaptation Effects 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 210000004961 autolysosome Anatomy 0.000 description 6
- 230000004908 autophagic flux Effects 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 102100021633 Cathepsin B Human genes 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 101000905743 Homo sapiens Cyclic AMP-dependent transcription factor ATF-4 Proteins 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 108091000080 Phosphotransferase Proteins 0.000 description 5
- 102100027565 Proteasome inhibitor PI31 subunit Human genes 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 210000000805 cytoplasm Anatomy 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 102000020233 phosphotransferase Human genes 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 238000003757 reverse transcription PCR Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 4
- 102100020814 Sequestosome-1 Human genes 0.000 description 4
- 230000022131 cell cycle Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000000368 destabilizing effect Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000001394 metastastic effect Effects 0.000 description 4
- 206010061289 metastatic neoplasm Diseases 0.000 description 4
- 210000003463 organelle Anatomy 0.000 description 4
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 4
- 229960000639 pazopanib Drugs 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000005747 tumor angiogenesis Effects 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 3
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 3
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 description 3
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000011122 anti-angiogenic therapy Methods 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 210000001163 endosome Anatomy 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000020477 pH reduction Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000004064 recycling Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- FSASIHFSFGAIJM-UHFFFAOYSA-N 3-methyladenine Chemical compound CN1C=NC(N)=C2N=CN=C12 FSASIHFSFGAIJM-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 102100022595 Broad substrate specificity ATP-binding cassette transporter ABCG2 Human genes 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108090000712 Cathepsin B Proteins 0.000 description 2
- 102000004225 Cathepsin B Human genes 0.000 description 2
- 208000030808 Clear cell renal carcinoma Diseases 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 2
- 101000644537 Homo sapiens Sequestosome-1 Proteins 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 2
- AJMOLNFDYWTVQW-QWRGUYRKSA-N L-leucyl-l-leucine methyl ester Chemical compound COC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C AJMOLNFDYWTVQW-QWRGUYRKSA-N 0.000 description 2
- 108010009491 Lysosomal-Associated Membrane Protein 2 Proteins 0.000 description 2
- 108010064171 Lysosome-Associated Membrane Glycoproteins Proteins 0.000 description 2
- 102000014944 Lysosome-Associated Membrane Glycoproteins Human genes 0.000 description 2
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 2
- 102100038225 Lysosome-associated membrane glycoprotein 2 Human genes 0.000 description 2
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 2
- 108091008606 PDGF receptors Proteins 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 108010004729 Phycoerythrin Proteins 0.000 description 2
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 2
- 102100032709 Potassium-transporting ATPase alpha chain 2 Human genes 0.000 description 2
- 101800001821 Precursor of protein E3/E2 Proteins 0.000 description 2
- 101710093109 Proteasome inhibitor PI31 subunit Proteins 0.000 description 2
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 2
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 2
- 108010083204 Proton Pumps Proteins 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000002886 autophagic effect Effects 0.000 description 2
- 150000007514 bases Chemical class 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229960000397 bevacizumab Drugs 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 230000010001 cellular homeostasis Effects 0.000 description 2
- 230000030570 cellular localization Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 206010073251 clear cell renal cell carcinoma Diseases 0.000 description 2
- 238000009643 clonogenic assay Methods 0.000 description 2
- 231100000096 clonogenic assay Toxicity 0.000 description 2
- 230000008045 co-localization Effects 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000001687 destabilization Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 239000003596 drug target Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000012405 in silico analysis Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 108010062054 leucyl-leucine-methyl ester Proteins 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 210000002487 multivesicular body Anatomy 0.000 description 2
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 2
- 230000000683 nonmetastatic effect Effects 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 101800002664 p62 Proteins 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000008823 permeabilization Effects 0.000 description 2
- 238000002135 phase contrast microscopy Methods 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000004626 scanning electron microscopy Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 1
- 238000010176 18-FDG-positron emission tomography Methods 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- ZCXUVYAZINUVJD-AHXZWLDOSA-N 2-deoxy-2-((18)F)fluoro-alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H]([18F])[C@@H](O)[C@@H]1O ZCXUVYAZINUVJD-AHXZWLDOSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 108010085376 Activating Transcription Factor 4 Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000012110 Alexa Fluor 594 Substances 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108010081642 CA 074 methyl ester Proteins 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 108010022637 Copper-Transporting ATPases Proteins 0.000 description 1
- 102100027591 Copper-transporting ATPase 2 Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- LYRLCJQODZGYDV-UHFFFAOYSA-N DND-153 dye Chemical compound C12=NC3=CC=CC=C3N2C(=O)C2=CC=CC3=C2C1=CC=C3NCCN(C)C LYRLCJQODZGYDV-UHFFFAOYSA-N 0.000 description 1
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102100023078 Early endosome antigen 1 Human genes 0.000 description 1
- 230000004668 G2/M phase Effects 0.000 description 1
- 102100029974 GTPase HRas Human genes 0.000 description 1
- 241000237858 Gastropoda Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 101000823298 Homo sapiens Broad substrate specificity ATP-binding cassette transporter ABCG2 Proteins 0.000 description 1
- 101000936280 Homo sapiens Copper-transporting ATPase 2 Proteins 0.000 description 1
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 1
- 101000779418 Homo sapiens RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- 101000742596 Homo sapiens Vascular endothelial growth factor C Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108010078049 Interferon alpha-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 108700042652 LMP-2 Proteins 0.000 description 1
- 108700026569 LMP7 Proteins 0.000 description 1
- 101150048357 Lamp1 gene Proteins 0.000 description 1
- 108010009254 Lysosomal-Associated Membrane Protein 1 Proteins 0.000 description 1
- 101710116782 Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 1
- 108010068342 MAP Kinase Kinase 1 Proteins 0.000 description 1
- 108010090306 Member 2 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 101150097381 Mtor gene Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710084225 Proteasome subunit beta type-10 Proteins 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 1
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 1
- 101710141955 RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 description 1
- 101150099493 STAT3 gene Proteins 0.000 description 1
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 description 1
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 1
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 1
- 102100038217 Vascular endothelial growth factor B Human genes 0.000 description 1
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 description 1
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 1
- 108010065472 Vimentin Proteins 0.000 description 1
- 102000013127 Vimentin Human genes 0.000 description 1
- -1 [18F]fluoro-2-deoxy-2-d-glucose Chemical compound 0.000 description 1
- QPMSXSBEVQLBIL-CZRHPSIPSA-N ac1mix0p Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1.O([C@H]1[C@]2(OC)C=CC34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O QPMSXSBEVQLBIL-CZRHPSIPSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000005735 apoptotic response Effects 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000009789 autophagic cell death Effects 0.000 description 1
- 210000004957 autophagosome Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000009668 clonal growth Effects 0.000 description 1
- 238000010293 colony formation assay Methods 0.000 description 1
- 230000001609 comparable effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- GLNDAGDHSLMOKX-UHFFFAOYSA-N coumarin 120 Chemical compound C1=C(N)C=CC2=C1OC(=O)C=C2C GLNDAGDHSLMOKX-UHFFFAOYSA-N 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- MCBBFDNTCVNDCE-UHFFFAOYSA-N cyclopenta-1,3-diene cyclopenta-2,4-diene-1-carbonyl cyanide iron(2+) Chemical compound [Fe++].c1cc[cH-]c1.O=C(C#N)[c-]1cccc1 MCBBFDNTCVNDCE-UHFFFAOYSA-N 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000009513 drug distribution Methods 0.000 description 1
- 108010037434 early endosome antigen 1 Proteins 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 230000000546 effect on cell death Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 102000004632 fms-Like Tyrosine Kinase 3 Human genes 0.000 description 1
- 108010003374 fms-Like Tyrosine Kinase 3 Proteins 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 108010014050 glucose 6-phosphate(transporter) Proteins 0.000 description 1
- BBKFSSMUWOMYPI-UHFFFAOYSA-N gold palladium Chemical compound [Pd].[Au] BBKFSSMUWOMYPI-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000007424 high content screening assay Methods 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 210000005008 immunosuppressive cell Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000012625 in-situ measurement Methods 0.000 description 1
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical class C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229950000038 interferon alfa Drugs 0.000 description 1
- 229960003521 interferon alfa-2a Drugs 0.000 description 1
- 230000007154 intracellular accumulation Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000006655 lysosomal degradation pathway Effects 0.000 description 1
- 230000008824 lysosomal permeabilization Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229960000901 mepacrine Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- XGWSRLSPWIEMLQ-YTFOTSKYSA-N methyl n-({(2s,3s)-3-[(propylamino)carbonyl]oxiran-2-yl}carbonyl)-l-isoleucyl-l-prolinate Chemical compound CCCNC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@H](C(=O)OC)CCC1 XGWSRLSPWIEMLQ-YTFOTSKYSA-N 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 238000004377 microelectronic Methods 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 238000013059 nephrectomy Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000007959 normoxia Effects 0.000 description 1
- 238000003499 nucleic acid array Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012660 pharmacological inhibitor Substances 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 230000009443 proangiogenesis Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000012342 propidium iodide staining Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 230000032537 response to toxin Effects 0.000 description 1
- TUFFYSFVSYUHPA-UHFFFAOYSA-M rhodamine 123 Chemical compound [Cl-].COC(=O)C1=CC=CC=C1C1=C(C=CC(N)=C2)C2=[O+]C2=C1C=CC(N)=C2 TUFFYSFVSYUHPA-UHFFFAOYSA-M 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940034785 sutent Drugs 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 229940099039 velcade Drugs 0.000 description 1
- 210000005048 vimentin Anatomy 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Definitions
- the invention relates to methods for treating a patient with VEGFR inhibitor-resistant metastatic renal cell carcinoma (mRCC).
- mRCC VEGFR inhibitor-resistant metastatic renal cell carcinoma
- Metastatic Renal Cell Carcinomas are highly vascularized tumors that are a paradigm for the treatment with anti-angiogenesis drugs particularly with tyrosine kinase inhibitors targeting the Vascular Endothelial Growth Factor (VEGF) pathway.
- VEGF Vascular Endothelial Growth Factor
- the available drugs increase the time to progression but are not curative and the patients eventually relapse.
- These inhibitors include notably sunitinib 1 , which since 2006 is considered as the standard first line treatment option for this disease.
- Sunitinib has been designed to disrupt major signaling pathways (HRAS/RAF 1/MAP2K1 , 2/MAPK1, 3 and MTOR pathways) that are responsible for the abnormal proliferation of cancer cells and tumor angiogenesis.
- sunitinib has not significantly improved the overall survival of the majority of patients compared to treatment with interferon alpha or interleukin 2 (median time of survival after the diagnosis of about 20 months) 1 2 , the standard treatments used before the development of anti-angiogenesis drugs. Moreover, the fact that mRCC patients gradually become refractory to sunitinib represents an important obstacle to better outcome for patients.
- sunitinib induced autophagy in bladder cancer cells 5 and that inhibition of autophagy potentiated the anti-pro liferative effects of sunitinib 6 7 .
- cells were exposed to high doses of sunitinib and the cells were not representative of cancers for which sunitinib is the treatment of reference 6 .
- Lysosomal sequestration of sunitinib 8 may be explained by the fact that it is a hydrophobic weak base (pKa 8.95).
- Sequestration in lysosomes may prevent access of the drug to the kinase domain of tyrosine kinase receptors present in the cytoplasm, thus participating in the loss of efficacy of the drug.
- sunitinib has not been described for mRCC cells.
- autophagy and lysosome trapping in the mechanisms of resistance has not been addressed.
- the invention relates to a drug or a combination of drugs selected from the group consisting of a proteasome inhibitor, an efflux inhibitor or a combination of an efflux inhibitor and a lysosomotropic agent for use in a method for treating metastatic renal cell carcinoma (mRCC) in a patient with an acquired resistance to treatment with a multi- targeted weak base vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI).
- mRCC metastatic renal cell carcinoma
- VAGFR multi- targeted weak base vascular endothelial growth factor receptor
- TKI tyrosine kinase inhibitor
- the invention in a second aspect, relates to a method for predicting the survival time of a patient affected with RCC or mRCC comprising the steps of : (i) determining the expression level of at least one of the proteasome component genes selected from the group consisting of PSMB8, PSMB9, PSMB10 and PSMF1 genes in a primary renal tumor biopsy obtained from said patient; (ii) comparing the level determined at step (i) with a predetermined reference level; and (iii) concluding that the patient has a poor prognosis when the level determined at step (i) is higher than the predetermined reference level.
- the invention relates to a combination comprising a multi-targeted weak base VEGFR TKI and a proteasome inhibitor or a combination comprising a multi- targeted weak base VEGFR TKI and an efflux inhibitor for use in a method for treating RCC or mRCC and/or preventing metastasis in a patient determined as having a poor prognosis according to the method of the invention.
- the invention in a fourth aspect, relates to a method for determining whether a patient affected with RCC or mRCC has or is at risk of multi-targeted weak base VEGFR TKI- resistance, comprising a step of determining the expression level of at least one of the proteasome component genes selected from the group consisting of PSMB8, PSMB9, PSMB10 and PSMF1 genes in a primary renal tumor biopsy obtained from said patient; (ii) comparing the level determined at step (i) with a predetermined reference level; and (iii) concluding that the patient has or is at risk of multi-targeted weak base VEGFR TKI- resistance when the level determined at step (i) is higher than the predetermined reference level.
- the invention relates to a combination comprising a multi-targeted weak base VEGFR TKI and a proteasome inhibitor or a combination comprising a multi- targeted weak base VEGFR TKI and an efflux inhibitor for use in a method for treating RCC or mRCC and/or preventing metastasis and/or preventing acquired resistance to treatment with a multi-targeted weak base VEGFR TKI in a patient determined as having or being at risk of multi-targeted weak base VEGFR TKI-resistance according to the method of the invention.
- the invention addresses these needs, as it relates to methods and treatment approaches useful in the treatment of VEGFR inhibitor-resistant metastatic renal cell carcinoma (mRCC).
- mRCC VEGFR inhibitor-resistant metastatic renal cell carcinoma
- the inventors have indeed focused their attention on the molecular mechanisms leading to resistance to sunitinib, the first line treatment of mRCC. Because of the anarchic vascularization of tumors the core of mRCC tumors receives sub-optimal concentrations of the drug. To mimic this in vivo situation, which is encountered in a neo-adjuvant setting, they exposed sunitinib-sensitive mRCC cells to concentrations of sunitinib below the concentration of the drug that gives 50% inhibition of cell proliferation (IC50). At these concentrations, sunitinib accumulated in lysosomes, which down-regulated the activity of the lysosomal protease cathepsin B and led to incomplete autophagic flux.
- Amino acid deprivation which initiates autophagy enhanced sunitinib resistance through the amplification of auto-lysosome formation.
- Sunitinib stimulated the expression of ABCB1, which participates in the accumulation of the drug in auto-lysosomes and favor its cellular efflux. Inhibition of this transporter by elacridar and the permeabilization of lysosome membranes with Leu-Leu-O- Methyl (LLOM) re-sensitized mRCC cells that were resistant to concentrations of sunitinib superior to the IC50.
- LLOM Leu-Leu-O- Methyl
- Proteasome inhibitors also induced the death of resistant cells suggesting that the ubiquitin-proteasome system compensates inhibition of autophagy to maintain a cellular homeostasis. Based on the present results, they propose a new therapeutic approach combining sunitinib with molecules that prevent lysosomal accumulation or inhibit the proteasome.
- a first aspect of the invention relates to a drug or a combination of drugs selected from the group consisting of a proteasome inhibitor, an efflux inhibitor or a combination of an efflux inhibitor and a lysosomotropic agent for use in a method for treating metastatic renal cell carcinoma (mRCC) in a patient with an acquired resistance to treatment with a multi-targeted weak base vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI).
- mRCC metastatic renal cell carcinoma
- VAGFR vascular endothelial growth factor receptor
- TKI tyrosine kinase inhibitor
- proteasome inhibitor or “inhibitor of the ubiquitin- proteasome system” (UPS) refers to compounds which inhibits the activity of the proteasome, more particularly its enzymatic activity. Inhibiting UPS enzymatic activity means reducing the ability of a UPS component to perform its activity.
- Such compounds include, but are not limited to, bortezomib (also known as PS-341), MLN 341, carfilzomib, delanzomib (also known as CEP-18770) and MG132.
- the proteasome inhibitor is bortezomib.
- Bortezomib is commercially available from Millennium under the trade name Velcade® and may be prepared for example as described in EP788360, EP1312609, EP1627880, US 6066730 and US 6083903 or by processes analogous thereto.
- efflux inhibitor refers to compound that inhibits the expression and/or activity of at least one transport protein (e.g., a P-Glycoprotein (P-GP)).
- P-GP P-Glycoprotein
- the efflux inhibitor is a P-Glycoprotein (ABCB1) inhibitor.
- the P-Glycoprotein (ABCB1) inhibitor is selected from the group consisting of elacridar, biricodar, pantoprazole, and tariquidar.
- lysosomotropic agent refers to a compound, which diffuses into cellular lysosomes, causes a decrease in the lysosome transmembrane proton gradient, and increases the pH inside the organelle.
- the lysosomotropic agent is selected from the group consisting of Leu-Leu-OMe (LLME), chloroquine, hydroxychloroquine, 3- methyladenine, quinacrine, mefloquine, monensin and bafilomycin Al .
- LLME Leu-Leu-OMe
- chloroquine hydroxychloroquine
- 3- methyladenine quinacrine
- mefloquine monensin and bafilomycin Al
- the terms “combination” refers to a "kit-of-parts" in the sense that the combination partners as defined above can be dosed independently or by use of different fixed combinations with distinguished amounts of the combination partners, i.e. simultaneously or at different time points.
- the parts of the kit of parts can then, e.g., be administered simultaneously or chronologically staggered, that is at different time points and with equal or different time intervals for any part of the kit of parts.
- the ratio of the total amounts of the combination partners to be administered in the combined preparation can vary.
- the combination partners can be administered by the same route or by different routes. When the administration is sequential, the first partner may be for instance administered 1 , 2, 3, 4, 5, 6, 7, days before the second partner.
- treatment refers to an approach for obtaining beneficial or desired results, including clinical results.
- beneficial or desired clinical results can include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions, diminishment of extent of disease, stabilized (i.e. not worsening) state of disease, preventing spread of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable.
- treatment may also mean prolonging survival as compared to expected survival if not receiving treatment.
- vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor refers to a compound which lead to the intracellular inhibition of VEGF signaling pathway by targeting the intracellular kinase domains of the three VEGFRs (VEGF receptor [VEGFR]- 1, VEGFR-2, and VEGFR-3).
- multi-targeted VEGFR TKI refers to a compound which inhibits several kinase targets in addition to the VEGFRs (e.g. platelet-derived growth factor receptor [PDGFR], stem cell factor receptor [c-kit] and FMS-like tyrosine kinase-3 [Flt3]).
- the term “weak base” refers to a compound which in an aqueous environment exists in an equilibrium between a neutrally charged basic form which is a proton acceptor (also referred to as a "non-protonated” form) and a positively charged conjugate acid form which is a proton donor (also referred to as a "protonated” form).
- the pKa is higher than a typical physiological pH, for example in a range from 7-12, and preferably from 8-10, such that the weak base exists predominantly in a positively charged (protonated) form at both a lysosomal pH and at the physiological pH.
- the multi-targeted weak base VEGFR TKI is selected from the group consisting of sunitinib, axitinib and dovitinib.
- said targeted weak base VEGFR TKI is sunitinib.
- the term "sunitinib” (also known as SU-11248 and marked as Sutent®) refers to a member of a family of pyrrole substituted 2-indolinone compounds, reported as being receptor tyrosine kinase inhibitors (see, U.S. Pat. Nos. 6,573,293 and 7,211,600). Sunitinib inhibits cellular signaling via a variety of receptors which play a role in tumor angiogenesis and tumor cell proliferation. Hence, the simultaneous inhibition of these receptors promotes reduced tumor vascularization and cancer cell death.
- drug resistant refers to a condition which demonstrates acquired resistance.
- “acquired resistance” is meant a multifactorial phenomenon occurring in tumor formation and progression that can influence the sensitivity of cancer cells to a drug. Acquired resistance may be due to several mechanisms such as but not limited to; alterations in drug-targets, decreased drug accumulation, alteration of intracellular drug distribution, reduced drug-target interaction, increased detoxification response, cell-cycle deregulation, increased damaged-DNA repair, and reduced apoptotic response. Several of said mechanisms can occur simultaneously and/or may interact with each other.
- Various qualitative and/or quantitative methods may be used to determine if a patient has developed or is susceptible to developing a resistance to treatment with a multi-targeted weak base VEGFR TKI such as sunitinib. For example, a patient who showed initial improvement while taking a multi-targeted weak base VEGFR TKI, may display signs that the multi-targeted weak base VEGFR TKI has become less effective or is no longer effective.
- Symptoms that may be associated with resistance to a multi-targeted weak base VEGFR TKI include, for example, a decline or plateau of the well-being of the patient, an increase in the size of a tumor, arrested or slowed decline in growth of a tumor, and/or the spread of cancerous cells in the body from one location to other organs, tissues or cells.
- a decrease in the sensitivity of cancer cells to a multi-targeted weak base VEGFR TKI, an increase in the growth or proliferation of cancer cells, and/or a decrease in cancer cell apoptosis as compared to a control may also be indicative that the patient has developed or is susceptible to developing a resistance to a multi-targeted weak base VEGFR TKI. It is possible to determine cancer cell sensitivity, growth, proliferation or apoptosis using standard methods as described further herein. For example, cancer cell sensitivity, growth, proliferation or apoptosis may be determined either in situ or in vitro.
- In situ measurements may involve, for example, observing the effect of a multi- targeted weak base VEGFR TKI therapy in a patient by examining cancer growth or metastasis.
- RECIST criteria are analyzed.
- RECIST Response Evaluation Criteria In Solid Tumors
- CT computed tomography
- a patient is considered as resistant when at least a 30 % increase of metastases is detected in said patient by [ 18 F]fluoro-2-deoxy-2-d-glucose (FDG) positron emission tomography (PET) imaging (FDG-PET scan).
- FDG fluoro-2-deoxy-2-d-glucose
- PET positron emission tomography
- the patient with an acquired resistance is still under multi-targeted weak base VEGFR TKI treatment.
- the invention relates to a method for treating metastatic renal cell carcinoma (mRCC) in a patient with an acquired resistance to treatment with a multi-targeted weak base vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) comprising the followings steps of: a) selecting a patient with mRCC who has developed a resistance to treatment with a VEGFR, and b) administering to said patient an therapeutically effective amount of a drug or a combination of drugs selected from the group consisting of a proteasome inhibitor, an efflux inhibitor or a combination of an efflux inhibitor and a lysosomotropic agent.
- mRCC metastatic renal cell carcinoma
- VEGFR vascular endothelial growth factor receptor
- TKI tyrosine kinase inhibitor
- terapéuticaally effective amount is meant an amount sufficient to achieve a concentration of compound which is capable of preventing or slowing down the disease to be treated. Such concentrations can be routinely determined by those of skilled in the art.
- the amount of the polypeptide actually administered will typically be determined by a physician or a veterinarian, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the patient, the severity of the subject's symptoms, and the like. It will also be appreciated by those of skilled in the art that the dosage may be dependent on the stability of the administered compound.
- the compounds of the invention may be administered by any means that achieve the intended purpose.
- administration may be achieved by a number of different routes including, but not limited to, subcutaneous, intravenous or parenteral, intramuscular, intraperitoneal or oral routes. Parenteral route is particularly preferred. Dosages to be administered depend on individual needs, on the desired effect and the chosen route of administration. It is understood that the dosage administered will be dependent upon the age, sex, health, and weight of the recipient, concurrent treatment, if any, frequency of treatment, and the nature of the effect desired. The total dose required for each treatment may be administered by multiple doses or in a single dose.
- the doses used for the administration can be adapted as a function of various parameters, and in particular as a function of the mode of administration used, of the relevant pathology, or alternatively of the desired duration of treatment.
- the daily dosage of the polypeptides may be varied over a wide range from 0.01 to 1,000 mg per adult per day.
- the compositions contain 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 250 and 500 mg of the active ingredient for the symptomatic adjustment of the dosage to the subject to be treated.
- a medicament typically contains from about 0.01 mg to about 500 mg of the active ingredient, preferably from 1 mg to about 100 mg of the active ingredient.
- An effective amount of the drug is ordinarily supplied at a dosage level from 0.0002 mg/kg to about 20 mg/kg of body weight per day, especially from about 0.001 mg/kg to 10 mg/kg of body weight per day.
- the invention in a second aspect, relates to a method for predicting the survival time of a patient affected with RCC or mRCC comprising the steps of : (i) determining the expression level of at least one of the proteasome component genes selected from the group consisting of PSMB8, PSMB9, PSMB10 and PSMF1 genes in a primary renal tumor biopsy obtained from said patient; (ii) comparing the level determined at step (i) with a predetermined reference level; and (iii) concluding that the patient has a poor prognosis when the level determined at step (i) is higher than the predetermined reference level.
- the invention in a third aspect, relates to a method for determining whether a patient affected with RCC or mRCC has or is at risk of multi-targeted weak base VEGFR TKI- resistance, comprising (i) a step of determining the expression level of at least one of the proteasome component genes selected from the group consisting of PSMB8, PSMB9, PSMB10 and PSMF1 genes in a primary renal tumor biopsy obtained from said patient; (ii) comparing the level determined at step (i) with a predetermined reference level; and (iii) concluding that the patient has or is at risk of multi-targeted weak base VEGFR TKI- resistance when the level determined at step (i) is higher than the predetermined reference level.
- the term "Proteasome subunit beta type-8 (PSMB8) gene” encodes a protein of 204 amino acids, member of the proteasome B-type family, also known as the TIB family, which is a 20S core beta subunit. This term includes naturally occurring PSMB8 and variants thereof.
- the naturally occurring human PSMB8 protein has an amino acid sequence as shown in UniProt Accession number P28062 and is encoded by the nucleic acid sequence provided in the GenBank database under accession number NM 004159.
- the term “Proteasome subunit beta type-9 (PSMB9) gene” encodes a protein of 199 amino acids, member of the proteasome B-type family. This term includes naturally occurring PSMB9 and variants thereof.
- the naturally occurring human PSMB9 protein has an amino acid sequence as shown in UniProt Accession number P28065 and is encoded by the nucleic acid sequence provided in the GenBank database under accession number NM 002800.
- PSMBIO Protein subunit beta type-9
- PSMFI Protein inhibitor PI31 subunit
- predetermined reference level refers to the expression levels of PSMB8, PSMB9, PSMBIO and PSMFI genes in biological samples obtained from the general population or from a selected population of patients.
- the selected population may be comprised of apparently RCC patients who had any sign or symptoms indicating the presence of a multi-targeted weak base VEGFR TKI-resistance.
- a predetermined reference level may be determined, for example, by determining the expression level ot PSMBS, PSMB9, PSMBIO and PSMFI nucleic acids or encoded polypeptides, in a corresponding biological sample obtained from one or more control patient(s) (e.g., no resistance or known not to be resistant).
- a higher or increased levels determined in a biological sample is indicative for example that said patient has or is at risk of having has or is at risk of multi-targeted weak base VEGFR TKI-resistance.
- the predetermined reference level may be established based upon comparative measurements between patients classified with no resistance and patients with established resistance.
- the predetermined reference value can be a threshold value or a range.
- a threshold value can also be arbitrarily selected based upon the existing experimental and/or clinical conditions, as would be recognized by a person of ordinary skilled in the art. For example, retrospective measurement of the expression level of the gene(s) of interest in properly banked historical subject samples may be used in establishing the predetermined reference value.
- the threshold value has to be determined in order to obtain the optimal sensitivity and specificity according to the function of the test and the benefit/risk balance (clinical consequences of false positive and false negative).
- the optimal sensitivity and specificity (and so the threshold value) can be determined using a Receiver Operating Characteristic (ROC) curve based on experimental data.
- ROC Receiver Operating Characteristic
- a "higher” or “increased” level refers to a expression level in a biological sample (i.e. a primary renal tumor biopsy obtained from the patient) which is at least 20% higher, in an embodiment at least 30% higher, in a further embodiment at least 40% higher; in a further embodiment at least 50% higher, in a further embodiment at least 100% higher (i.e. 2-fold), in a further embodiment at least 200% higher (i.e. 3-fold), in a further embodiment at least 300% higher (i.e. 4-fold), relative to the predetermined reference level.
- Determination of the expression level of PSMB8, PSMB9, PSMB10 and/or PSMF1 genes may be performed by a variety of techniques.
- the expression level as determined is a relative expression level.
- the determination comprises contacting the biological sample with selective reagents such as probes, primers or ligands, and thereby detecting the presence, or measuring the amount, of polypeptide or nucleic acids of interest originally in said biological sample. Contacting may be performed in any suitable device, such as a plate, micro titer dish, test tube, well, glass, column, and so forth. In specific embodiments, the contacting is performed on a substrate coated with the reagent, such as a nucleic acid array or a specific ligand array.
- the substrate may be a solid or semi- so lid substrate such as any suitable support comprising glass, plastic, nylon, paper, metal, polymers and the like.
- the substrate may be of various forms and sizes, such as a slide, a membrane, a bead, a column, a gel, etc.
- the contacting may be made under any condition suitable for a detectable complex, such as a nucleic acid hybrid or an antibody-antigen complex, to be formed between the reagent and the nucleic acids or polypeptides of the biological sample.
- determining includes qualitative and/or quantitative detection (i.e. detecting and/or measuring the expression level) with or without reference to a control or a predetermined value.
- detecting means determining if PSMB8, PSMB9, PSMBIO and/or PSMFI is present or not in a biological sample and “measuring” means determining the amount of PSMB8, PSMB9, PSMBIO and/or PSMFI in a biological sample.
- the expression level may be determined for example by RT-PCR or immunohistochemistry (IHC) performed on a primary renal tumor biopsy.
- the expression level of PSMB8, PSMB9, PSMBIO and/or PSMFI genes may be assessed by determining the quantity of mRNA.
- nucleic acid contained in the biological samples e.g., cell or tissue prepared from the patient
- the nucleic acid contained in the biological samples is first extracted according to standard methods, for example using lytic enzymes or chemical solutions or extracted by nucleic-acid-binding resins following the manufacturer's instructions.
- the extracted mRNA is then detected by hybridization (e.g., Northern blot analysis) and/or amplification (e.g., RT-PCR).
- Quantitative or semi-quantitative RT-PCR is preferred. Real-time quantitative or semi-quantitative RT-PCR is particularly advantageous.
- nucleic acids having at least 10 nucleotides and exhibiting sequence complementarity or homology to the mRNA of interest herein find utility as hybridization probes or amplification primers. It is understood that such nucleic acids need not be identical, but are typically at least about 80% identical to the homologous region of comparable size, more preferably 85% identical and even more preferably 90-95% identical. In certain embodiments, it will be advantageous to use nucleic acids in combination with appropriate means, such as a detectable label, for detecting hybridization. A wide variety of appropriate indicators are known in the art including, fluorescent, radioactive, enzymatic or other ligands (e. g. avidin/biotin).
- Probes typically comprise single-stranded nucleic acids of between 10 to 1000 nucleotides in length, for instance of between 10 and 800, more preferably of between 15 and 700, typically of between 20 and 500.
- Primers typically are shorter single- stranded nucleic acids, of between 10 to 25 nucleotides in length, designed to perfectly or almost perfectly match a nucleic acid of interest, to be amplified.
- the probes and primers are "specific" to the nucleic acids they hybridize to, i.e. they preferably hybridize under high stringency hybridization conditions (corresponding to the highest melting temperature Tm, e.g., 50 % formamide, 5x or 6x SCC.
- SCC is a 0.15 M NaCl, 0.015 M Na-citrate).
- the nucleic acid primers or probes used in the above-mentioned methods may be assembled as a kit.
- a kit includes consensus primers and molecular probes.
- a particular kit also includes the components necessary to determine if amplification has occurred.
- the kit may also include, for example, PCR buffers and enzymes; positive control sequences, reaction control primers; and instructions for amplifying and detecting the specific sequences.
- the invention also relates to a kit for performing the above-mentioned methods, wherein said kit comprises means for determining the expression level of the PSMB8, PSMB9, PSMB10 and/or PSMF1 genes in a biological sample of interest.
- the methods of the invention comprise the steps of providing total R As extracted from a primary renal tumor biopsy and subjecting the RNAs to amplification and hybridization to specific probes, more particularly by means of a quantitative or semi-quantitative RT-PCR.
- the expression level of PSMB8, PSMB9, PSMB10 and/or PSMF1 genes may be assessed by determining the quantity of proteins encoded by said genes.
- Such methods comprise a step of contacting the biological sample with a binding partner capable of selectively interacting with a marker protein present in the biological sample.
- the binding partner is generally an antibody that may be polyclonal or monoclonal, preferably monoclonal.
- Monoclonal antibodies directed against PSMB8, PSMB9, PSMB10 and/or PSMF1 are well known from the skilled man in the art such as the antibodies commercialized by
- PSMB8, PSMB9, PSMB10 and/or PSMF1 proteins may be detected using standard electrophoretic and immunodiagnostic techniques, including immunoassays such as competition, direct reaction, or sandwich type assays.
- immunoassays include, but are not limited to, Western blots; agglutination tests; enzyme-labelled and mediated immunoassays, such as ELISAs; biotin/avidin type assays; radioimmunoassays; Immunoelectrophoresis; immunoprecipitation, etc.
- the reactions generally include revealing labels such as fluorescent, chemiluminescent, radioactive, enzymatic labels or dye molecules, or other methods for detecting the formation of a complex between the antigen and the antibody or antibodies reacted therewith.
- Labels are known in the art that generally provide (either directly or indirectly) a signal (e.g. fluorescein isothiocyanate (FITC) or phycoerythrin (PE)).
- FITC fluorescein isothiocyanate
- PE phycoerythrin
- an immunohistochemistry (IHC) method may be used on a primary renal tumor biopsy. IHC specifically provides a method of detecting a target protein in a biological sample or tissue specimen in situ. The overall cellular integrity of the biological sample is maintained in IHC, thus allowing detection of both the presence and location of the target of interest.
- IHC Intra-human immunosorbent assays
- a biological sample is fixed with formalin, embedded in paraffin and cut into sections for staining and subsequent inspection by light microscopy.
- Current methods of IHC use either direct labelling or secondary antibody-based or hapten-based labelling.
- Examples of known IHC systems include, for example, En Vision TM (DakoCytomation), Powervision® (Immunovision, Springdale, AZ), the NBATM kit (Zymed Laboratories Inc., South San Francisco, CA), HistoFine ® (Nichirei Corp, Tokyo, Japan).
- the invention relates to a combination comprising a multi-targeted weak base VEGFR TKI and a proteasome inhibitor or a combination comprising a multi- targeted weak base VEGFR TKI and an efflux inhibitor for use in a method for treating RCC or mRCC and/or preventing metastasis in a patient determined as having a poor prognosis according to a method of the invention as above-defined.
- the combination further comprises a lysosomotropic agent as previously described.
- the invention relates to a combination comprising a multi- targeted weak base VEGFR TKI and a proteasome inhibitor or a combination comprising a multi-targeted weak base VEGFR TKI and an efflux inhibitor for use in a method for treating RCC or mRCC and/or preventing metastasis and/or preventing acquired resistance to treatment with a multi-targeted weak base VEGFR TKI in a patient determined as having or being at risk of multi-targeted weak base VEGFR TKI-resistance according to a method of the invention as above-defined.
- the combination further comprises a lysosomotropic agent as previously described.
- FIGURES are a diagrammatic representation of FIGURES.
- Figure 1 A sunitinib concentration below the IC50 slowed down cell proliferation but did not induce cell death.
- A General scheme illustrating the different concentrations to which RCC cells may be exposed to in a tumor.
- B The proliferative capacity of 786-0 cells in the absence (Ct) or presence of increasing concentrations of sunitinib (sun) was evaluated by counting the cells at the indicated times. Data are the mean fold increase ⁇ SD. The fold increase of untreated cells was taken as the reference value for statistics. Statistical significances of the results compared to untreated cells are indicated; */? ⁇ 0.05; **p ⁇ 0.01; ***/? ⁇ 0.001.
- ABC transporters reverted sunitinib resistance of 786-OR cells. Determination of the percentage of dead 786-OS and 786-OR cells after incubation for 24 hours with the indicated combinations of drugs (sunitinib (sun) 2.5 ⁇ /L; LLOM (L) 1 ⁇ /L; elacridar (E) 5 ⁇ /L). * p ⁇ 0.05; *** p ⁇ 0.001.
- Figure 3 Primary tumor cells derived from a patient who progressed on sunitinib were sensitive to sunitinib when in the presence of elacridar or LLOM.
- proteasome inhibitors MG132 (mg, 10 ⁇ /L) or bortezomib (borte, 5 ⁇ /L) alone or in combination with sunitinib (sun, 2.5 ⁇ /L) decreased the viability of 786-OS and 786- OR cells after incubation for 24 hours. ** p ⁇ 0.01; *** p ⁇ 0.001, NS (non significant).
- Figure 5 Description of the different phases of events justifying a combinatorial approach for treatment.
- the proteasome degrades misfolded proteins and participates in recycling of amino acids.
- the lysosome destabilizing agent Leu-Leu-O- Methyl (LLOM) prevents the trapping of sunitinib in lysosomes so the drug is localizes to the cytoplasm but is "taken in charge” by the ABCG1, which transport the drug out of the cell thus leading to intermediate resistance (++).
- LLOM Leu-Leu-O- Methyl
- Maximal sensitivity to sunitinib can be obtained by destabilization of lysosomes with LLOM combined with inhibitors of ABC transporters (Elacridar) or with proteasome inhibitors (MG132 (mg) or bortezomib (borte)).
- Figure 6 LLOM, elacridar, bafilomycin or a combination of these different drugs alone or with sunitinib induced a higher mortality in 786-OS cells than in 786-OR cells.
- A Effect of increasing concentrations of elacridar (E) on cell viability after incubation for 24 hours. * p ⁇ 0.05; ** p ⁇ 0.01; *** p ⁇ 0.001.
- B Effect of increasing concentrations of LLOM (L) on cell viability after incubation for 24 hours. ** p ⁇ 0.01.
- Figure 7 The combination of a lysosomal destabilizing agent and an inhibitor of ABC transporters reverts sunitinib resistance of RCC 10 cells. Determination of the percentage viable of RCC 1 OS and RCC 1 OR cells after incubation for 24 hours with the indicated combinations of drugs sunitinib (sun 2.5 mmol/L), LLOM (L 1 mmol/L), elacridar (E 5 mmol/L). * p ⁇ 0.05; ** p ⁇ 0.01.
- Figure 8 Proteasome inhibitors induced the death of cells resistant to sunitinib.
- proteasome inhibitors MG132 (mg, 10 ⁇ /L) or bortezomib (borte, 5 ⁇ /L) alone or in combination with sunitinib (sun, 2.5 ⁇ /L for RCC 10 cells and 5 ⁇ /L for CC cells) decreased the viability of RCC 1 OS, RCC 1 OR (A) and CC cells (B) after incubation for 24 hours.
- Figure 9 Analysis of cbioportal databases highlighted the prognostic value of a cluster of proteasome associated genes.
- A Heatmaps of three microarrays (GSE 14494, 11151 and 22541) for the relative expression of PSMB8, PSMB9, PSMBIO and PSMFl).
- B Kaplan-Meier analysis of overall survival of patients with RCC at cbioportal. Overall survival was calculated from patient subgroups with mRNA levels for PSMB8, PSMB9, PSMBIO and PSMFl that were 1.4 less or greater than the median value. Statistical significance (p value) is indicated.
- C Kaplan-Meier analysis of disease free survival or overall survival of patients with non metastatic (M0) or metastatic (M+) RCC. Statistical significance (p value) is indicated.
- EXAMPLE Resistance to sunitinib in renal clear cell carcinoma results from sequestration in lysosomes and inhibition of the autophagic flux.
- Anti- LAMP1 (H4A3) and anti-EEAl (N-19) were from Santa-Cruz
- anti SQSTM1 was from BD Bioscience
- CTSB (Ab-1) was purchased from Merck
- anti LAMP2 was from Abeam (H4B4)
- anti-ARDl antibodies were produced and characterized in our laboratory 50
- anti-actin (1-19) was from Santa-Cruz
- anti-AKTl (9272) anti-phospho MAPK1/3 at Thrl85/Tyrl87 and Thr202/Tyr204 (4370)
- anti-MAPKl/3 (137F5) antibodies were all obtained from Cell Signaling Technology.
- Hank's Balanced Salt Solution (HBSS) was from Life technology.
- Cell culture Human 786-0 cells were purchased from the American Tissue Culture
- RCC10 cells were a kind gift from W.H. Kaelin (Dana-Farber Cancer Institute, Boston, MA) and were used in one of our published studies 51 .
- RCC cells were grown in DMEM supplemented with 7% FCS at 37°C in a humidified atmosphere containing 5% C0 2 .
- HBSS experiments cells were pre-incubated in HBSS for 30 minutes before sunitinib treatment for 24 hours for the determination of cell viability.
- clonogenic assays cells were incubated for seven days in fresh medium after the same procedure. Resistant cells were obtained by chronic exposure to increasing concentrations of sunitinib up to 8 ⁇ /L.
- An INVIVO2 200 workstation (Ruskinn Technology Biotrace International Pic) set at 1% oxygen, 94% nitrogen and 5% carbon dioxide was used for hypoxic conditions.
- Cells were seeded in six-well dishes and transiently treated with sunitinib the following day. Cells were next detached from days 2 to 6 and counted with a Coulter counter (Beckman) in duplicate to assess cell proliferation. Cell viability and cell death was assessed using the ADAM-MC apparatus (NanoEnTek) based on fluorescent propidium iodide staining according to the manufacturer's instructions.
- Colony formation assay RCC cells (500 cells per condition) were treated or not with sunitinib. Colonies were detected after 10 days of culture. Cells were then washed, fixed at room temperature for 20 minutes with 3% paraformaldehyde and colored by crystal violet.
- RTCA Real-Time Cell Analyzer
- Immunoblotting Cells treated with sunitinib and/or exposed to pharmacological inhibitors, were lysed in buffer containing 3% SDS, 10% glycerol, 0.825mM Na 2 HP04. Samples (30 ⁇ g) were separated by 10%> SDS-PAGE, transferred onto a PVDF membrane (Immobilon, Millipore, France) and then exposed to the appropriate antibodies: anti-LC3, anti-p62, anti-LAMPl, anti-ARDl, anti-cathepsin B or anti-actin. Proteins were visualized with the ECL system using horseradish peroxidase-conjugated anti-rabbit or anti-mouse secondary antibodies.
- Sub-cellular fractionation was performed using proteo- extract sub-cellular proteome extraction kit according to the manufacturer's instructions (Calbiochem).
- Flow Cytometry - Cell cycle distribution Cells were trypsinized, washed and re- suspended in cold 70% ethanol overnight. After 2 washes with PBS, cells were re-suspended in propidium iodide (40 ⁇ g/ml) containing ribonuclease A (10 ⁇ g/ml) for 15 min at room temperature and were analyzed using a fluorescence-activated cell sorter (BD healthcare F AC S C ALIBUR, analyzer).
- BD healthcare F AC S C ALIBUR fluorescence-activated cell sorter
- CTSB activity RCC cells treated with sunitinib for 24 h were lysed for 30 min at 4°C in lysis buffer (400 mmol/L Na Phosphate pH 6, 150 mmol/L NaCl, 4 mmol/L ethylene- diaminetetraacetic acid, 1 mmol/L phenylmethylsulfonyl fluoride, 10 ⁇ g/ml aprotinin and 1% Triton X-100) and lysates were cleared at lOOOOg for 15 min at 4°C. Each assay (in quadruplicate) was performed with 50 ⁇ g of protein prepared from control or sunitinib treated cells.
- lysis buffer 400 mmol/L Na Phosphate pH 6, 150 mmol/L NaCl, 4 mmol/L ethylene- diaminetetraacetic acid, 1 mmol/L phenylmethylsulfonyl fluoride, 10 ⁇ g/ml aprotinin
- cellular extracts were incubated in a 96-well plate, with 60 ⁇ of z-RR-AMC (7-amino-4-methylcoumarin) as substrate for various times at 37°C.
- the CTSB activity was measured by following the emission at 460 nm (excitation at 390 nm) in the presence or absence of 1 ⁇ of CA-074Me (an inhibitor of CTSB activity). Enzyme activities were expressed in arbitrary units per mg of protein.
- mRCC cells showed reduced proliferation in the presence of concentrations of sunitinib below the IC50 (sub-optimal concentration):
- Fig. 1A Because of the abnormal vascularization of tumors, the core of primary mRCC or metastases is not exposed to optimal concentrations of the drug (Fig. 1A).
- Fig. 1A We first determined the in vitro concentrations that resulted in progressive adaptation to sunitinib and final selection of resistant cells.
- the plasma concentrations of patients or mice exposed to sunitinib was low (0.1-1 ⁇ /L range) compared to the intra-tumor amount, which was ten times higher (10 ⁇ /L range).
- the IC50 of endothelial cells for sunitinib was approximately 0.1 ⁇ ⁇ / ⁇ 9
- the IC50 of mRCC cells was approximately 5 ⁇ /L 3 ' 8
- mRCC cells (Fig. IB, C) have a reduced proliferation rate, which was linked to prolonged S and G2/M phases of the cell cycle (Fig. ID).
- a sub-optimal concentration of sunitinib (2.5 ⁇ /L) did not affect cell viability (Fig. ID, E) whereas exposure to a higher concentration resulted in cell death, as measured by cell counting or a clonogenic assay.
- Phase contrast microscopy highlighted a modification of the cell shape and the appearance of a yellowish color inside the cells after incubation with sunitinib for two days.
- the intracellular localization of sunitinib was confirmed by visualization of its auto- fluorescence.
- Sunitinib auto-fluorescence co-localized with a specific lysosomal staining (Lysosome- Associated Membrane Protein 1 (LAMPl)) confirming that sunitinib accumulated in acidic lysosomal structures. Accumulation in lysosomes was also observed in two independent cell lines (RCC10 and A498) and two RCC primary cell lines (CC and TFE3) that we previously described 3 .
- sunitinib did not accumulate in early endosomes (no co-localization with the early endosome antigen 1 (EEAl)). This result suggests accumulation of sunitinib in intracellular compartments with no major consequences to cell viability. This characteristic defines sunitinib as a lysomotropic agent 10 . FACS analysis showed that sunitinib accumulated in lysosomes in a time-dependent manner and that there was an increase in the lysosomal mass, which coincided with increased expression of LAMP 1. Such accumulation of sunitinib was not dependent on the oxygen concentration since sunitinib sequestration was equivalent in normoxia or hypoxia.
- sunitinib neutralized the pH of lysosomes and inhibited CTSB/cathepsin B:
- Sunitinib is a weak base (pKa 8.95), which accumulates in lysosomes where it is protonated by a pH-partitioning process 10 . Once ionized, sunitinib becomes membrane impermeable with the impossibility of diffusing out of the organelle, which results in lysosome trapping. Accumulation continues as long as the low pH is maintained by the vacuolar proton pump (V-type H+ATPase) but ultimately results in buffering of the acidic pH of lysosomes.
- V-type H+ATPase vacuolar proton pump
- the lysosensor DND-153 fluorescence (pKa 7.5) was intense in control conditions (this dye fluoresces in an acidic environment) but almost disappeared in the presence of sunitinib suggesting that the acidic pH of lysosomes has been neutralized. This correlated with decreased expression and activity of one of the major lysosome-associated proteases CTSB.
- autophagy is responsible for the degradation of dysfunctional organelles and proteins and allows cell survival during nutrient deprivation n . So, autophagy is important in maintaining cell homeostasis, but if exacerbated, it can lead to cell death 12 . Sunitinib treatment resulted in an increase in the lysosomal pH and inhibition of the lysosomal protease activity. Hence, we investigated the consequences of these modifications on autophagy. Autophagy is characterized by the accumulation of lipidated forms of LC3 (LC3-II) and the degradation of SQSTMl/p62 protein.
- LC3-II lipidated forms of LC3
- Phase contrast microscopy clearly showed an enhanced accumulation of yellow granules when cells are cultured in HBSS medium. Quantification by FACS confirmed this qualitative observation. A high concentration (10 ⁇ /L) of sunitinib induces cell death, but at a lower concentrations (2.5 ⁇ /L), it slows proliferation without inducing cell death, as expected. However, if the cells were first cultured in HBSS medium, cell proliferation was minimally affected by 2.5 ⁇ /L sunitinib and cell death was substantially decreased, even at a high concentration of the drug (10 ⁇ /L). These results were confirmed with two other independent cell lines (RCC10 and A498 cells).
- sunitinib-resistant cells by chronic exposure of cells to the drug (786-OR and RCCIOR). Incomplete autophagy in these cells was attested by accumulation of LC3-II and sustained expression of SQSTMl/p62.
- Primary sunitinib-resistant cells were also derived from a RCC removed surgically from a patient, as we previously described (TFE3 cells) 3 . The 786-OR and RCC10R cells survive and proliferate in the presence of a high concentration of the drug, which is sufficient to induce parental cell death.
- TFE3 cells are highly resistant to sunitinib in vitro even at high concentrations of the drug (IC50 10 ⁇ /L) 3 .
- the ability to accumulate sunitinib inside 786-OR was increased compare to parental cells. As shown previously by Gotink et al. 8 , resistance (maintained several weeks) was not genetically acquired since it could be reverted by culturing the cells in the absence of the drug for a few passages (not shown). Electron microscopy showed that 786-OR cells accumulate bigger vacuolar structures, identified above as auto-lysosomes, compared to 786-OS cells when incubated in the presence of 2.5 ⁇ /L of sunitinib, a finding in favor of an exacerbated incomplete autophagy.
- elacridar an inhibitor of ABC transporters, induced slightly 786-OS cell death at a low concentration (1 ⁇ /L) (Fig. 6A), it potentiated sunitinib activity on 786-OS cells (Fig. 2).
- Elacridar did not significantly mediate 786-OR cell death when alone (Fig. 6A) but potentiated sunitinib activity (Fig. 2).
- the lysomotropic agent LLOM had little effect on cell death at a low concentration (1 ⁇ /L). Higher concentrations are needed to induce cell death probably through the release of cathepsins and induction of lysosome membrane permeabilization leading finally to apoptosis 17 (Fig. 6B).
- bafilomycin an inhibitor of the V-ATPase pump, which is responsible for the maintenance of the low pH of the lysosomes, exerted a comparable effect to LLOM (Fig. 6D).
- the triple combination sunitinib/bafilomycin/elacridar was less potent than the sunitinib/LLOM/elacridar mix.
- Equivalent results were obtained with an independent cell line (RCC10, Fig. 7).
- Elacridar and LLOM alone or in combination had no effect on TFE3 cell viability.
- Elacridar was more active in the presence of a concentration of 2.5 ⁇ /L sunitinib, (55% cell death) but this was not the case for the LLOM/sunitinib combination.
- massive TFE3 cell death was obtained with the triple combination (Fig. 3).
- Lysosomal trapping reduces the activity of sunitinib, since its targets, the kinase domain of tyrosine kinase receptors are located in the cytoplasm. This mechanism has been described in chronic myeloid leukemia for which agents that destabilize lysosomes revert resistance to imatinib 17 .
- axitinib and dovitinib can be protonated at physiological pH and subsequently trapped in the lysosomes. Hence, resistance mechanisms equivalent to that described herein for sunitinib may be the cause of reduced efficacy of these drugs.
- Pazopanib another ATP mimetic approved for the treatment of mRCC is the only drug that cannot be protonated and trapped in the lysosomes, hence not concerned by this mechanism of resistance.
- sunitinib and pazopanib show the same overall survival 31 , but pazopanib is preferred by physicians and patients mainly for its better quality of life 32 .
- drugs that are lysosomotropic shared certain physicochemical properties, possessing a ClogP>2 and a basic pKa between 6.5 and 11, predictably influenced their intracellular localization 33 .
- the inventors also observed that the amine group of sunitinib, added to improve the solubility of the drug is responsible for the high pKa value.
- the synthesis of an analog of sunitinib devoid of this amine group may prevent its accumulation in lysosomes.
- ATF4 is a major transcription factor implicated in the adaptation to nutrient stress of tumor cells 35 .
- ATF4 has also been implicated in resistance to cisplatin and cells overexpressing ATF4 showed multidrug resistance 36 .
- ATF4 may be the driver of a transcriptional program leading to expression of ABCG1, as previously shown 37 38 .
- ABCG1 may be due to a lack of its degradation.
- membrane proteins including receptors and transporters, recycle to the plasma membrane through the recycling endosomal system.
- Some cargo proteins sort cell membranes and discarded proteins into internal luminal vesicles of multi-vesicular bodies (early endosomes), and mature multi-vesicular bodies (late endosomes) that can fuse with lysosomes for proteolysis by lysosomal enzymes.
- the lysosomal degradation pathway is impaired because of the modification of the lysosomal pH and could explain the decrease in ABCG1 degradation and its subsequent accumulation. Similar consequences were observed with chloroquine treatment, which resulted in Notch 1 accumulation due to a decrease in the activity of lysosomes 39 .
- Lysosomal sequestration is rapid, occurring as soon as the drug is in contact with the target cells, and does not modify the genetic program.
- Recent studies have also demonstrated that numerous cancer cells have defective acidification of their lysosomes.
- lysomotropic agents would be in contact with their targets in the cytoplasm of cancer cells devoid of lysosome trapping 40 .
- This elegant approach would limit toxicity to normal cell and would concentrate the cytotoxic/cytostatic effects on tumor cells.
- they showed that the acidification of the lysosomes of mRCC cells was not defective. They observed that the TFE3 cells were resistant to a high concentration of sunitinib (IC50 10 ⁇ /L).
- proteasome associated genes that are over- expressed in primary and mRCC but also in paired pulmonary metastasis (Fig. 9 A,) 44-45 .
- the proteins encoded by these genes comprised a subset of the proteasome beta sub-units that affect the generation of peptides to promote efficient antigen recognition (PSMB8/ Proteasome subunit beta type-8, PSMB9/ Proteasome subunit beta type-9, PSMB10/ Proteasome subunit beta type- 10) and a cellular regulator of proteasome formation and of proteasome-mediated antigen processing (PSMFl /Proteasome inhibitor PI31 subunit) 47 .
- Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res 2010; 70: 1053-62.
- tanton MJ Dutta S, Zhang H, Polavaram NS, Leontovich AA, Honscheid P, Sinicrope
- Bevacizumab can induce reactivity to VEGF-C and -D in human brain and tumour derived endothelial cells. J Neurooncol 2011; 104: 103-12.
- Ferrara N Role of myeloid cells in vascular endothelial growth factor-independent tumor angiogenesis. Curr Opin Hematol 2010; 17:219-24.
- Activating transcription factor 4 confers a multidrug resistance phenotype to gastric cancer cells through transactivation of SIRT1 expression.
- Zaiss DM, Standera S, Kloetzel PM, Sijts AJ. PI31 is a modulator of proteasome formation and antigen processing. Proc Natl Acad Sci U S A 2002; 99: 14344-9.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne des méthodes de traitement de patients souffrant d'un adénocarcinome métastatique (mRCC) résistant aux inhibiteurs du VEGFR. Plus particulièrement, l'invention concerne un médicament ou une combinaison de médicaments sélectionnés dans le groupe constitué d'un inhibiteur de protéasome, d'un inhibiteur d'efflux ou d'une combinaison d'un inhibiteur d'efflux et d'un agent lysosomotrope, destinés à être utilisés dans une méthode de traitement du mRCC chez le patient présentant une résistance acquise au traitement par un inhibiteur multi-cible à base faible des tyrosines kinases (TKI) associées au VEGFR.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15305732 | 2015-05-15 | ||
EP15305732.8 | 2015-05-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016184793A1 true WO2016184793A1 (fr) | 2016-11-24 |
Family
ID=53177314
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2016/060806 WO2016184793A1 (fr) | 2015-05-15 | 2016-05-13 | Méthodes de traitement de patients souffrant d'un adénocarcinome rénal métastatique résistant aux inhibiteurs du vegfr |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2016184793A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018189403A1 (fr) | 2017-04-14 | 2018-10-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes et compositions pharmaceutiques destinées au traitement du cancer |
CN110575540A (zh) * | 2018-06-07 | 2019-12-17 | 中山大学附属第六医院 | Pdgf抑制剂用于制备治疗肠道炎症疾病的药物方面的用途 |
CN112423765A (zh) * | 2018-04-25 | 2021-02-26 | 儿童医学中心公司 | Abcb5配体和底物 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0788360A1 (fr) | 1994-10-28 | 1997-08-13 | Proscript, Inc. | Composes d'esters et d'acides boroniques, leur synthese et leurs utilisations |
US6573293B2 (en) | 2000-02-15 | 2003-06-03 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
US7211600B2 (en) | 1999-12-22 | 2007-05-01 | Sugen Inc. | Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds |
-
2016
- 2016-05-13 WO PCT/EP2016/060806 patent/WO2016184793A1/fr active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0788360A1 (fr) | 1994-10-28 | 1997-08-13 | Proscript, Inc. | Composes d'esters et d'acides boroniques, leur synthese et leurs utilisations |
US6066730A (en) | 1994-10-28 | 2000-05-23 | Proscript, Inc. | Boronic ester and acid compounds, synthesis and uses |
US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
EP1312609A1 (fr) | 1994-10-28 | 2003-05-21 | Millennium Pharmaceuticals, Inc. | Composés d'esters et acides boroniques, leur synthèse et utilisations |
EP1627880A1 (fr) | 1994-10-28 | 2006-02-22 | Millennium Pharmaceuticals, Inc. | Composés d'esters et acides boroniques, leur synthèse et utilisations |
US7211600B2 (en) | 1999-12-22 | 2007-05-01 | Sugen Inc. | Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds |
US6573293B2 (en) | 2000-02-15 | 2003-06-03 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
Non-Patent Citations (58)
Title |
---|
ABDEL-AZIZ AK; SHOUMAN S; EL-DEMERDASH E; ELGENDY M; ABDEL-NAIM AB.: "Chloroquine synergizes sunitinib cytotoxicity via modulating autophagic, apoptotic and angiogenic machineries", CHEM BIOL INTERACT, vol. 217, 2014, pages 28 - 40, XP029021679, DOI: doi:10.1016/j.cbi.2014.04.007 |
BERGERS G; HANAHAN D.: "Modes of resistance to anti-angiogenic therapy", NAT REV CANCER, vol. 8, 2008, pages 592 - 603, XP055095845, DOI: doi:10.1038/nrc2442 |
BILTON R; MAZURE N; TROTTIER E; HATTAB M; DERY MA; RICHARD DE; POUYSSEGUR J; BRAHIMI-HORN MC.: "Arrest-defective-1 protein, an acetyltransferase, does not alter stability of hypoxia-inducible factor (HIF)-lalpha and is not induced by hypoxia or HIF", J BIOL CHEM, vol. 280, 2005, pages 31132 - 40 |
CAO Y; HOEPPNER LH; BACH S, E G; GUO Y; WANG E; WU J; COWLEY MJ; CHANG DK; WADDELL N ET AL.: "Neuropilin-2 promotes extravasation and metastasis by interacting with endothelial alpha5 integrin", CANCER RES, vol. 73, 2013, pages 4579 - 90 |
CERAMI E; GAO J; DOGRUSOZ U; GROSS BE; SUMER SO; AKSOY BA; JACOBSEN A; BYRNE CJ; HEUER ML; LARSSON E ET AL.: "The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data", CANCER DISCOV, vol. 2, 2012, pages 401 - 4 |
COLETTA A; MOLTER C; DUQUE R; STEENHOFF D; TAMINAU J; DE SCHAETZEN V; MEGANCK S; LAZAR C; VENET D; DETOURS V ET AL.: "InSilico DB genomic datasets hub: an efficient starting point for analyzing genome-wide studies in GenePattern, Integrative Genomics Viewer, and R/Bioconductor", GENOME BIOL, vol. 13, 2012, pages R104, XP021129484, DOI: doi:10.1186/gb-2012-13-11-r104 |
DUVVURI M; GONG Y; CHATTCRJI D; KRISE JP.: "Weak base permeability characteristics influence the intracellular sequestration site in the multidrug-resistant human leukemic cell line HL-60", J BIOL CHEM, vol. 279, 2004, pages 32367 - 72 |
DUVVURI M; KONKAR S; HONG KH; BLAGG BS; KRISE JP: "A new approach for enhancing differential selectivity of drugs to cancer cells", ACS CHEM BIOL, vol. 1, 2006, pages 309 - 15 |
EBOS JM; KERBEL RS.: "Antiangiogenic therapy: impact on invasion, disease progression, and metastasis", NAT REV CLIN ONCOL, vol. 8, 2011, pages 210 - 21 |
EBOS JM; LEE CR; CRUZ-MUNOZ W; BJARNASON GA; CHRISTENSEN JG; KERBEL RS.: "Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis", CANCER CELL, vol. 15, 2009, pages 232 - 9 |
EINSELE H.: "Bortezomib", RECENT RESULTS CANCER RES, vol. 201, 2014, pages 325 - 45 |
ESCUDIER B; BELLMUNT J; NEGRIER S; BAJETTA E; MELICHAR B; BRACARDA S; RAVAUD A; GOLDING S; JETHWA S; SNELLER V.: "Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival", J CLIN ONCOL, vol. 28, 2010, pages 2144 - 50 |
ESCUDIER B; PORTA C; BONO P; POWLES T; EISEN T; STERNBERG CN; GSCHWEND JE; DE GIORGI U; PARIKH O; HAWKINS R ET AL.: "Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study", J CLIN ONCOL, vol. 32, 2014, pages 1412 - 8, XP055323197, DOI: doi:10.1200/JCO.2013.50.8267 |
FALASCA M; LINTON KJ.: "Investigational ABC transporter inhibitors", EXPERT OPIN INVESTIG DRUGS, vol. 21, 2012, pages 657 - 66 |
FERRARA N.: "Role of myeloid cells in vascular endothelial growth factor-independent tumor angiogenesis", CURR OPIN HEMATOL, vol. 17, 2010, pages 219 - 24 |
G. V. KONDAGUNTA: "Phase II Trial of Bortezomib for Patients With Advanced Renal Cell Carcinoma", JOURNAL OF CLINICAL ONCOLOGY, vol. 22, no. 18, 9 August 2004 (2004-08-09), US, pages 3720 - 3725, XP055244973, ISSN: 0732-183X, DOI: 10.1200/JCO.2004.10.155 * |
GAO J; AKSOY BA; DOGRUSOZ U; DRESDNER G; GROSS B; SUMER SO; SUN Y; JACOBSEN A; SINHA R; LARSSON E ET AL.: "Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal", SCI SIGNAL, vol. 6, 2013, XP055297746, DOI: doi:10.1126/scisignal.2004088 |
GIULIANO S; PAGES G.: "Mechanisms of resistance to anti-angiogenesis therapies", BIOCHIMIE, vol. 95, 2013, pages 1110 - 9, XP028593704, DOI: doi:10.1016/j.biochi.2013.03.002 |
GOTINK KJ; BROXTERMAN HJ; LABOTS M; DE HAAS RR; DEKKER H; HONEYWELL RJ; RUDEK MA; BEEREPOOT LV; MUSTERS RJ; JANSEN G ET AL.: "Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance", CLIN CANCER RES, vol. 17, 2011, pages 7337 - 46 |
GRAU S; THORSTEINSDOTTIR J; VON BAUMGARTEN L; WINKLER F; TONN JC; SCHICHOR C.: "Bevacizumab can induce reactivity to VEGF-C and -D in human brain and tumour derived endothelial cells", J NEUROONCOL, vol. 104, 2011, pages 103 - 12, XP019935346, DOI: doi:10.1007/s11060-010-0480-6 |
GREPIN R; AMBROSETTI D; MARSAUD A; GASTAUD L; AMIEL J; PEDEUTOUR F; PAGES G.: "The relevance of testing the efficacy of anti-angiogenesis treatments on cells derived from primary tumors: a new method for the personalized treatment of renal cell carcinoma", PLOS ONE, vol. 9, 2014, pages E89449 |
GREPIN R; GUYOT M; GIULIANO S; BONCOMPAGNI M; AMBROSETTI D; CHAMOREY E; SCOAZEC JY; NEGRIER S; SIMONNET H; PAGES G.: "The CXCL7/CXCR1/2 axis is a key driver in the growth of clear cell renal cell carcinoma", CANCER RES, vol. 74, 2014, pages 873 - 83 |
HAMDAN AM; KOYANAGI S; WADA E; KUSUNOSE N; MURAKAMI Y; MATSUNAGA N; OHDO S.: "Intestinal expression of mouse Abcg2/breast cancer resistance protein (BCRP) gene is under control of circadian clock-activating transcription factor-4 pathway", J BIOL CHEM, vol. 287, 2012, pages 17224 - 31 |
HIROMI SATO ET AL: "Abstract 983: A dual inhibitor of MDR-1 and ABCG2,elacridar, enhances cytotoxic effects of sunitinib on RCC cell lines.", 15 April 2015 (2015-04-15), 104th Annual Meeting of the American-Association-for-Cancer-Research (AACR); Washington, DC, USA; April 06 -10, 2013, pages 983, XP055222438, Retrieved from the Internet <URL:http://cancerres.aacrjournals.org/content/73/8_Supplement/983> [retrieved on 20151020] * |
HIROMI SATO ET AL: "Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 746, 1 January 2015 (2015-01-01), NL, pages 258 - 266, XP055222418, ISSN: 0014-2999, DOI: 10.1016/j.ejphar.2014.11.021 * |
HUANG D; DING Y; LI Y; LUO WM; ZHANG ZF; SNIDER J; VANDENBELDT K; QIAN CN; TEH BT.: "Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.", CANCER RES, vol. 70, 2010, pages 1053 - 62 |
IGARASHI T; IZUMI H; UCHIUMI T; NISHIO K; ARAO T; TANABE M; URAMOTO H; SUGIO K; YASUMOTO K; SASAGURI Y ET AL.: "Clock and ATF4 transcription system regulates drug resistance in human cancer cell lines", ONCOGENE, vol. 26, 2007, pages 4749 - 60 |
IKEDA T; ISHII KA; SAITO Y; MIURA M; OTAGIRI A; KAWAKAMI Y; SHIMANO H; HARA H; TAKEKOSHI K.: "Inhibition of autophagy enhances sunitinib-induced cytotoxicity in rat pheochromocytoma PC12 cells", J PHARMACOL SCI, vol. 121, 2013, pages 67 - 73 |
J. AN ET AL: "Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib", MOLECULAR CANCER THERAPEUTICS, vol. 6, no. 1, 1 January 2007 (2007-01-01), US, pages 61 - 69, XP055244978, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-06-0255 * |
KALAYDA GV; WAGNER CH; BUSS I; REEDIJK J; JAEHDE U.: "Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells", BMC CANCER, vol. 8, 2008, pages 175, XP021034610 |
KAUIMANN AM; KRISE JP.: "Lysosomal sequestration of amine-containing drugs: analysis and therapeutic implications", J PHARM SCI, vol. 96, 2007, pages 729 - 46 |
KLIONSKY DJ; ABDALLA FC; ABELIOVICH H; ABRAHAM RT; ACEVEDO-AROZENA A; ADELI K; AGHOLME L; AGNELLO M; AGOSTINIS P; AGUIRRE-GHISO JA: "Guidelines for the use and interpretation of assays for monitoring autophagy", AUTOPHAGY, vol. 8, 2012, pages 445 - 544, XP009185550, DOI: doi:10.4161/auto.19496 |
LAMARK T; JOHANSEN T.: "Autophagy: links with the proteasome.", CURR OPIN CELL BIOL, vol. 22, 2010, pages 192 - 8 |
LUCIANI F; SPADA M; DE MILITO A; MOLINARI A; RIVOLTINI L; MONTINARO A; MARRA M; LUGINI L; LOGOZZI M; LOZUPONE F ET AL.: "Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs.", J NATL CANCER INST, vol. 96, 2004, pages 1702 - 13, XP002460053 |
MAES H; KUCHNIO A; PERIC A; MOENS S; NYS K; DE BOCK K; QUAEGEBEUR A; SCHOORS S; GEORGIADOU M; WOUTERS J ET AL.: "Tumor vessel normalization by chloroquine independent of autophagy", CANCER CELL, vol. 26, 2014, pages 190 - 206 |
MARTINEZ-ZAGUILAN R; LYNCH RM; MARTINEZ GM; GILLIES RJ.: "Vacuolar-type H(+)-ATPases are functionally expressed in plasma membranes of human tumor cells", AM J PHYSIOL, vol. 265, 1993, pages C1015 - 29 |
MEDIONI J ET AL: "Salvage Therapy with Bevacizumab-Sunitinib Combination after Failure of Sunitinib Alone for Metastatic Renal Cell Carcinoma: A Case Series", EUROPEAN UROLOGY, ELSEVIER BV, NL, vol. 56, no. 1, 1 July 2009 (2009-07-01), pages 207 - 211, XP026174083, ISSN: 0302-2838, [retrieved on 20090113], DOI: 10.1016/J.EURURO.2009.01.001 * |
MIZUSHIMA N; LEVINE B; CUERVO AM; KLIONSKY DJ.: "Autophagy fights disease through cellular self-digestion", NATURE, vol. 451, 2008, pages 1069 - 75 |
MOOTHA VK; LINDGREN CM; ERIKSSON KF; SUBRAMANIAN A; SIHAG S; LEHAR J; PUIGSERVER P; CARLSSON E; RIDDERSTRALE M; LAURILA E ET AL.: "PGC-1 alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes", NAT GENET, vol. 34, 2003, pages 267 - 73 |
MOTZER RJ; HUTSON TE; CELLA D; REEVES J; HAWKINS R; GUO J; NATHAN P; STAEHLER M; DE SOUZA P; MERCHAN JR ET AL.: "Pazopanib versus sunitinib in metastatic renal-cell carcinoma", N ENGL J MED, vol. 369, 2013, pages 722 - 31 |
MOTZER RJ; HUTSON TE; TOMCZAK P; MICHAELSON MD; BUKOWSKI RM; OUDARD S; NEGRIER S; SZCZYLIK C; PILI R; BJARNASON GA ET AL.: "Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma", J CLIN ONCOL, vol. 27, 2009, pages 3584 - 90, XP055159728, DOI: doi:10.1200/JCO.2008.20.1293 |
NADANACIVA S; LU S; GEBHARD DF; JESSEN BA; PENNIE WD; WILL Y.: "A high content screening assay for identifying lysosomotropic compounds", TOXICOL IN VITRO, vol. 25, 2011, pages 715 - 23, XP055279409, DOI: doi:10.1016/j.tiv.2010.12.010 |
PAEZ-RIBES M; ALLEN E; HUDOCK J; TAKEDA T; OKUYAMA H; VINALS F; INOUE M; BERGERS G; HANAHAN D; CASANOVAS O.: "Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis", CANCER CELL, vol. 15, 2009, pages 220 - 31 |
PAMER E; CRESSWELL P.: "Mechanisms of MHC class I--restricted antigen processing", ANNU REV IMMUNOL, vol. 16, 1998, pages 323 - 58, XP002339969, DOI: doi:10.1146/annurev.immunol.16.1.323 |
PUISSANT A; DUFIES M; RAYNAUD S; CASSUTO JP; AUBERGER P.: "Targeting lysosomes to eradicate imatinib-resistant chronic myelogenous leukemia cells.", LEUKEMIA, vol. 24, 2010, pages 1099 - 101 |
SANTONI M; AMANTINI C; MORELLI MB; LIBERATI S; FARFARIELLO V; NABISSI M; BONFILI L; ELEUTERI AM; MOZZICAFREDDO M; BURATTINI L ET A: "Pazopanib and sunitinib trigger autophagic and non-autophagic death of bladder tumour cells", BR J CANCER, vol. 109, 2013, pages 1040 - 50 |
SENNINO B; ISHIGURO-OONUMA T; SCHRIVER BJ; CHRISTENSEN JG; MCDONALD DM.: "Inhibition of c-Met reduces lymphatic metastasis in RIP-Tag2 transgenic mice", CANCER RES, vol. 73, 2013, pages 3692 - 703 |
SENNINO B; ISHIGURO-OONUMA T; WEI Y; NAYLOR RM; WILLIAMSON CW; BHAGWANDIN V; TABRUYN SP; YOU WK; CHAPMAN HA; CHRISTENSEN JG ET AL.: "Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors", CANCER DISCOV, vol. 2, 2012, pages 270 - 87, XP055084027, DOI: doi:10.1158/2159-8290.CD-11-0240 |
SHUKLA S; ROBEY RW; BATES SE; AMBUDKAR SV: "Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2", DRUG METAB DISPOS, vol. 37, 2009, pages 359 - 65 |
SPITZER M; WILDENHAIN J; RAPPSILBER J; TYERS M.: "BoxPlotR: a web tool for generation of box plots", NAT METHODS, vol. 11, 2014, pages 121 - 2 |
STANTON MJ; DUTTA S; ZHANG H; POLAVARAM NS; LEONTOVICH AA; HONSCHEID P; SINICROPE FA; TINDALL DJ; MUDERS MH; DATTA K.: "Autophagy control by the VEGF-C/NRP-2 axis in cancer and its implication for treatment resistance", CANCER RES, vol. 73, 2013, pages 160 - 71 |
SUBRAMANIAN A; TAMAYO P; MOOTHA VK; MUKHERJEE S; EBERT BL; GILLETTE MA; PAULOVICH A; POMEROY SL; GOLUB TR; LANDER ES ET AL.: "Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles", PROC NATL ACAD SCI U S A, vol. 102, 2005, pages 15545 - 50, XP002464143, DOI: doi:10.1073/pnas.0506580102 |
TANG SC; LAGAS JS; LANKHEET NA; POLLER B; HILLEBRAND MJ; ROSING H; BEIJNEN JH; SCHINKEL AH.: "Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration", INT J CANCER, vol. 130, 2012, pages 223 - 33 |
XIN H; ZHANG C; HERRMANN A; DU Y; FIGLIN R; YU H.: "Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells", CANCER RES, vol. 69, 2009, pages 2506 - 13 |
YAMAGISHI T; SAHNI S; SHARP DM; ARVIND A; JANSSON PJ; RICHARDSON DR.: "P-glycoprotein mediates drug resistance via a novel mechanism involving lysosomal sequestration", J BIOL CHEM, vol. 288, 2013, pages 31761 - 71 |
YE J; KUMANOVA M; HART LS; SLOANE K; ZHANG H; DE PANIS DN; BOBROVNIKOVA-MARJON E; DIEHL JA; RON D; KOUMENIS C.: "The GCN2-ATF4 pathway is critical for tumour cell survival and proliferation in response to nutrient deprivation", EMBO J, vol. 29, 2010, pages 2082 - 96 |
ZAISS DM; STANDERA S; KLOETZEL PM; SIJTS AJ.: "PI31 is a modulator of proteasome formation and antigen processing", PROC NATL ACAD SCI U S A, vol. 99, 2002, pages 14344 - 9, XP002245684, DOI: doi:10.1073/pnas.212257299 |
ZHU H; XIA L; ZHANG Y; WANG H; XU W; HU H; WANG J; XIN J; GANG Y; SHA S ET AL.: "Activating transcription factor 4 confers a multidrug resistance phenotype to gastric cancer cells through transactivation of SIRTI expression", PLOS ONE, vol. 7, 2012, pages E31431 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018189403A1 (fr) | 2017-04-14 | 2018-10-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes et compositions pharmaceutiques destinées au traitement du cancer |
CN112423765A (zh) * | 2018-04-25 | 2021-02-26 | 儿童医学中心公司 | Abcb5配体和底物 |
EP3784249A4 (fr) * | 2018-04-25 | 2022-03-02 | Children's Medical Center Corporation | Ligands abcb5 et substrats |
CN110575540A (zh) * | 2018-06-07 | 2019-12-17 | 中山大学附属第六医院 | Pdgf抑制剂用于制备治疗肠道炎症疾病的药物方面的用途 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2020198883A (ja) | 癌の分類および使用法 | |
US20210236500A1 (en) | Inhibition of autophagy using phospholipase a2 inhibitors | |
EP3077544B1 (fr) | Conception à base rationnelle d'une thérapie ciblée contre le cancer | |
JP2019534290A (ja) | 癌の治療方法において使用するためのファルネシルトランスフェラーゼ阻害剤 | |
NZ615738A (en) | Methods for predicting and improving the survival of gastric cancer patients | |
CN114126634A (zh) | 作为生物标志物的白介素-4诱导基因1(il4i1)及其用途 | |
WO2016184793A1 (fr) | Méthodes de traitement de patients souffrant d'un adénocarcinome rénal métastatique résistant aux inhibiteurs du vegfr | |
US20160015725A1 (en) | Methods of controlling tumor bioenergetics networks | |
WO2020023768A1 (fr) | Méthodes et matériels pour identifier et traiter des cancers résistants aux inhibiteurs de bet | |
US20120238562A1 (en) | Treatment of cancer by targeting molecules that influence mst1/stk4 signaling | |
US11209420B2 (en) | Cancer diagnostics, therapeutics, and drug discovery associated with macropinocytosis | |
JP2020508351A (ja) | ファルネシルトランスフェラーゼ阻害剤を用いてがんを治療する方法 | |
US20180346988A1 (en) | Znf532 for diagnosis and treatment of cancer | |
EP2699696A2 (fr) | Sous-typage moléculaire, pronostic et traitement du cancer de la prostate | |
EP3664807A2 (fr) | Procédés et matériaux permettant d'identifier et de traiter des cancers résistants aux inhibiteurs de bet | |
US10398672B2 (en) | Methods and compositions for targeting cancer stem cells | |
EP4361136A1 (fr) | Composé pour le traitement du glioblastome | |
US20230324392A1 (en) | Methods and compositions for targeting cytosolic dsdna signaling in chromosomally unstable cancers | |
JP6566431B2 (ja) | 抗腫瘍剤 | |
Van Eaton | Clinical importance of autophagy dependency and inhibition in cancer treatment | |
Doheny | Developing Pharmacological TGLI1 Inhibitors for the Treatment of Metastatic Breast Cancer | |
KR20220114238A (ko) | 암 전이 억제용 약학 조성물 | |
US20150065518A1 (en) | Methods of treating cancer having an active wnt/beta-catenin pathway | |
You et al. | Disruption of β-Catenin Destruction Complex by Ephexin1-Axin1 Interaction Promotes Colorectal Cancer Proliferation | |
Jathal | Subcellular Localization of ErbB3/HER3 and its Interactions with the Androgen Receptor In Prostate Cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16722238 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16722238 Country of ref document: EP Kind code of ref document: A1 |